-The Hindu This can help reconcile differences:WIPO Director-General Istanbul: The World Intellectual Property Organisation (WIPO), a United Nations body, has pointed out the need for a second interpretation of global intellectual property law, one that balances social benefit with the need to protect investment. This balancing could help reconcile the differences between developing nations such as India, and the concerns of multi-national companies and developed nations, according to Francis Gurry, Director-General of the...
More »SEARCH RESULT
Total Matching Records found : 110
2,644 died during clinical trial of drugs in 7 years: Govt to SC -Dhananjay Mahapatra
-The Times of India As many as 2,644 people, called subjects, died during the clinical trials of 475 new drugs on human beings in last seven years and only 17 of the medicines were approved for marketing in India, the Centre has informed the Supreme Court. Responding to allegations by NGO, Swasthya Adhikar Manch, in its PIL that Indians were used as guinea pigs by foreign pharmaceutical majors for human trial of...
More »Rajasthan govt to give free cancer drugs -Syed Intishab Ali
-The Times of India JAIPUR: In a major relief for blood cancer patients, the state's health department is all set to provide Imatinib tablets ("magic bullet" tablets) free of cost to them. The government's decision follows the April 1 Supreme Court decision to dismiss Swiss drug maker novartis AG's attempt to win patent protection for its cancer drug Glivec (Imatinib). Currently the tablet is sold in the market by novartis at...
More »Landmark verdict -V Venkatesan
-Frontline The Supreme Court's ruling against novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...
More »Why novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy
-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to novartis's application covering a beta crystalline form of imatinib -the medicine novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »
